X

Drug Profile

Research programme: anti-infectives - Triad Therapeutics

Alternative Names: EACPR inhibitors - Triad Therapeutics; Oxidoreductase inhibitors - Triad Therapeutics/Schering-Plough

Latest Information Update: 01 Mar 2007

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Schering-Plough; Triad Therapeutics
Class
Mechanism of Action Enzyme inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Methicillin-resistant Staphylococcus aureus infections; Mycoses

Most Recent Events

10 Dec 2004 Triad Therapeutics is ceasing operations and selling its assets
27 Aug 2003 Preclinical trials in Methicillin-resistant Staphylococcus aureus infections in USA (unspecified route)
27 Aug 2003 Preclinical trials in Mycoses in USA (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com